KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Receivables (2016 - 2025)

Novavax (NVAX) has 14 years of Receivables data on record, last reported at $124.9 million in Q4 2025.

  • For Q4 2025, Receivables rose 15.35% year-over-year to $124.9 million; the TTM value through Dec 2025 reached $124.9 million, up 15.35%, while the annual FY2025 figure was $124.9 million, 9.88% up from the prior year.
  • Receivables reached $124.9 million in Q4 2025 per NVAX's latest filing, up from $34.1 million in the prior quarter.
  • Across five years, Receivables topped out at $530.5 million in Q1 2022 and bottomed at $29.3 million in Q1 2024.
  • Average Receivables over 5 years is $184.4 million, with a median of $124.9 million recorded in 2022.
  • Peak YoY movement for Receivables: soared 579.57% in 2021, then tumbled 90.91% in 2024.
  • A 5-year view of Receivables shows it stood at $490.3 million in 2021, then tumbled by 74.54% to $124.8 million in 2022, then surged by 152.96% to $315.7 million in 2023, then plummeted by 65.7% to $108.3 million in 2024, then rose by 15.35% to $124.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $124.9 million in Q4 2025, $34.1 million in Q3 2025, and $226.4 million in Q2 2025.